Skip to content

Gilteritinib Fumarate

Generic Medicine With 1 Brands Available In Bangladesh. Read What It Is For And How It Is Taken, Then Compare The Brands By Strength, Maker And Price.

Generic Guide

About Gilteritinib Fumarate

What This Generic Is For, How It Is Taken, And What To Watch For.

Indications

Gilteritinib is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test

Dosage And Administration

Patient Selection: Select patients for the treatment of AML with Gilteritinib based on the presence of FLT3 mutations in the blood or bone marrow. Information on FDA-approved tests for the detection of a FLT3 mutation in AML is available. Recommended Dosage: The recommended starting dose of Gilteritinib is 120 mg orally once daily with or without food. Response may be delayed. In the absence of disease progression or unacceptable toxicity, treatment for a minimum of 6 months is recommended to allow time for a clinical response. Do not break or crush Gilteritinib tablets. Administer Gilteritinib tablets orally about the same time each day. If a dose of Gilteritinib is missed or not taken at the usual time, administer the dose as soon as possible on the same day, and at least 12 hours prior to the next scheduled dose. Return to the normal schedule the following day. Do not administer 2 doses within 12 hours. Dose Modification: Assess blood counts and blood chemistries, including creatine phosphokinase, prior to the initiation of Gilteritinib, at least once weekly for the first month, once every other week for the second month, and once monthly for the duration of therapy. Perform electrocardiogram (ECG) prior to initiation of treatment with Gilteritinib, on days 8 and 15 of cycle 1, and prior to the start of the next two subsequent cycles.

Side Effects

The following adverse drug reactions are described elsewhere in the labeling: Fever Dizziness or lightheadedness Cough Rapid weight gain Trouble breathing Swelling of your arms or legs Rash Decreased urination

Precautions And Warnings

Differentiation Syndrome: Of 319 patients treated with Gilteritinib in the clinical trials, 3% experienced differentiation syndrome. Differentiation syndrome is associated with rapid proliferation and differentiation of myeloid cells and may be life-threatening or fatal if not treated. Symptoms of differentiation syndrome in patients treated with Gilteritinib included fever, dyspnea, pleural effusion, pericardial effusion, pulmonary edema, hypotension, rapid weight gain, peripheral edema, rash, and renal dysfunction. Some cases had concomitant acute febrile neutrophilic dermatosis. Differentiation syndrome occurred as early as 2 days and up to 75 days after Gilteritinib initiation and has been observed with or without concomitant leukocytosis. Of the 11 patients who experienced differentiation syndrome, 9 (82%) recovered after treatment or after dose interruption of Gilteritinib. If differentiation syndrome is suspected, initiate dexamethasone 10 mg IV every 12 hours (or an equivalent dose of an alternative oral or IV corticosteroid) and hemodynamic monitoring until improvement. Taper corticosteroids after resolution of symptoms and administer corticosteroids for a minimum of 3 days. Symptoms of differentiation syndrome may recur with premature discontinuation of corticosteroid treatment. If severe signs and/or symptoms persist for more than 48 hours after initiation of corticosteroids, interrupt Gilteritinib until signs and symptoms are no longer severe. Posterior Reversible Encephalopathy Syndrome: Of 319 patients treated with Gilteritinib in the clinical trials, 1% experienced posterior reversible encephalopathy syndrome (PRES) with symptoms including seizure and altered mental status. Symptoms have resolved after discontinuation of Gilteritinib. A diagnosis of PRES requires confirmation by brain imaging, preferably magnetic resonance imaging (MRI). Discontinue Gilteritinib in patients who develop PRES. Prolonged QT Interval: Gilteritinib has been associated with prolonged cardiac ventricular repolarization (QT interval). Of the 317 patients with a post-baseline QTc measurement on treatment with Gilteritinib in the clinical trial, 1% were found to have a QTc interval greater than 500 msec and 7% of patients had an increase from baseline QTc greater than 60 msec. Perform electrocardiogram (ECG) prior to initiation of treatment with Gilteritinib, on days 8 and 15 of cycle 1, and prior to the start of the next two subsequent cycles. Interrupt and reduce Gilteritinib dosage in patients who have a QTcF >500 msec. Hypokalemia or hypomagnesemia may increase the QT prolongation risk. Correct hypokalemia or hypomagnesemia prior to and during Gilteritinib administration. Pancreatitis: Of 319 patients treated with Gilteritinib in the clinical trials, 4% experienced pancreatitis. Evaluate patients who develop signs and symptoms of pancreatitis. Interrupt and reduce the dose of Gilteritinib in patients who develop pancreatitis. Embryo-Fetal Toxicity: Based on findings in animals and its mechanism of action, Gilteritinib can cause embryo-fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of Gilteritinib to pregnant rats during organogenesis caused embryo-fetal lethality, suppressed fetal growth and teratogenicity at maternal exposures (AUC24) approximately 0.4 times the AUC24 in patients receiving the recommended dose. Advise females of reproductive potential to use effective contraception during treatment with Gilteritinib and for at least 6 months after the last dose of Gilteritinib. Advise males with female partners of reproductive potential to use effective contraception during treatment with Gilteritinib and for at least 4 months after the last dose of Gilteritinib. Pregnant women, patients becoming pregnant while receiving Gilteritinib or male patients with pregnant female partners should be apprised of the potential risk to the fetus.

Pregnancy And Lactation

Pregnancy: Based on findings from animal studies and its mechanism of action, Gilteritinib can cause fetal harm when administered to a pregnant woman. There are no available data on Gilteritinib use in pregnant women to inform a drug-associated risk of adverse developmental outcomes. In animal reproduction studies, administration of Gilteritinib to pregnant rats during organogenesis caused adverse developmental outcomes including embryo-fetal lethality, suppressed fetal growth, and teratogenicity at maternal exposures (AUC24) approximately 0.4 times the AUC24 in patients receiving the recommended dose. Advise pregnant women of the potential risk to a fetus. Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. Lactation: There are no data on the presence of Gilteritinib and/or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production. Following administration of radiolabeled Gilteritinib to lactating rats, milk concentrations of radioactivity were higher than radioactivity in maternal plasma at 4 and 24 hours post-dose. In animal studies, Gilteritinib and/or its metabolite(s) were distributed to the tissues in infant rats via the milk. Because of the potential for serious adverse reactions in a breastfed child, advise a lactating woman not to breastfeed during treatment with Gilteritinib and for at least 2 months after the last dose.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Clinical Details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Available Brand Names: 1

Sorted By
Tablet

Gilternib 40 mg

Generic: Gilteritinib Fumarate

670.00Taka / Unit

View Medicine

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250